Charles River Laboratories Intl. Inc vs Ecopetrol SA — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Ecopetrol SA trades at $16.94 (market cap $33.11B). The key difference: Ecopetrol SA is far larger — about 2.3× Charles River Laboratories Intl. Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Ecopetrol SA for 84 Days on average.
| CRL | EC | |
|---|---|---|
Market Cap | $14.23B | $33.11B |
Volume | 1,176,885 | 993,598 |
Sector | Health | Energy |
52-Week High | $310.77 | $18.26 |
52-Week Low | $149.93 | $8.61 |
Typical Hold Time | 33 Days | 84 Days |
Enterprise Value | $17.06B | $61.36B |
Dividend Yield | — | 3.83% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Ecopetrol (EC) trades at $16.94, up 1.86% with bearish technical signals despite attractive valuation metrics including a P/E of 7.97 and EV/EBITDA of 4. Recent earnings misses and declining revenue from $119.69T in 2025 contrast with management changes and government payment receipts highlighted in September 2026 news.
The stock faces headwinds from earnings volatility and political oversight risks, but low valuations and stable cash flows offer value potential. Analyst consensus is cautious with a $16.85 target, suggesting limited upside amid operational transitions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →